Opsis Therapeutics Announces Scientific Advisory Board Members
MADISON, Wis.--(BUSINESS WIRE)--Opsis Therapeutics ('Opsis'), a company developing treatments for retinal diseases, today announced the formation of its scientific advisory board (SAB). Approved by the executive leadership team, the SAB is established to advise on the development and advancement to the clinic of the Opsis pipeline of first-in-class retinal cell therapies. "We are thrilled to have such talented and experienced scientific advisors providing critical expertise to our team," said D